Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

MAF Induces Inflammatory Mediators Involved in the Pathogenesis of Primary Myelofibrosis

Samantha Ruberti, BSc, Elisa Bianchi, PhD, Tiziana Fanelli, MSc, Sebastiano Rontauroli, BSc, Valentina Pennucci, PhD, Giuditta Corbizzi Fattori, BSc, Carmela Mannarelli, MSc, PhD, Ruggiero Norfo, PhD, Chiara Rossi, BSc, Roberta Zini, PhD, Simona Salati, PhD, Zelia Prudente, PhD, Enrico Tagliafico, MDPhD, Paola Guglielmelli, MD PhD, Alessandro M. Vannucchi, MD, Rossella Manfredini, PhDBSc

Blood (2016) 128 (22): 3132.

https://doi.org/10.1182/blood.V128.22.3132.3132

Published: 2016

Journal Articles

Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group

Paola Guglielmelli, PhDMD, Giada Rotunno, MSc, PhD, Annalisa Pacilli, PhD, Elisa Rumi, MD, Vittorio Rosti, Federica Delaini, MD, Margherita Maffioli, MD, Tiziana Fanelli, MSc, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Daniela Pietra, PhD, Silvia Salmoiraghi, BSc, Carmela Mannarelli, MSc, PhD, Francesco Passamonti, MD, Alessandro Rambaldi, MD, Giovanni Barosi, Tiziano Barbui, MD, Mario Cazzola, MD, Alessandro M. Vannucchi, MD

Blood (2016) 128 (22): 943.

https://doi.org/10.1182/blood.V128.22.943.943

Published: 2016

Journal Articles

Prognotic Impact of Mutations in Systemic Mastocytosis

Lisa Pieri, MD PhD, Giada Rotunno, MSc, PhD, Francesca Gesullo, MSc, Tiziana Fanelli, MSc, Giuditta Corbizi Fattori, MSc, Annalisa Pacilli, PhD, Federica Scarfì, MD, Maria Loredana Iorno, MD, Fabio Almerigogna, MD, Roberto Salerno, MD, Paola Guglielmelli, MD PhD, Roberta Zanotti, MD, Alessandro M. Vannucchi, MD

Blood (2016) 128 (22): 1953.

https://doi.org/10.1182/blood.V128.22.1953.1953

Published: 2016

Journal Articles

Integrative Analysis of Copy Number and Gene Expression Data Suggests Novel Pathogenetic Mechanisms in Primary Myelofibrosis

Blood (2015) 126 (23): 2830.

https://doi.org/10.1182/blood.V126.23.2830.2830

Published: 2015

Journal Articles

Mutational Profile of Patients with Polycythemia Vera Treated with Ruxolitinib in the Phase III Controlled Response Study

Paola Guglielmelli, MD PhD, Annalisa Pacilli, PhD, Giada Rotunno, MSc, Alessandro Pancrazzi, BS, Tiziana Fanelli, MSc, Lisa Pieri, MD PhD, Raimonda Fjerza, MD, Chiara Paoli, BS, Lucia Merli, BSN, Marker Mahtab, Ana Rodriguez, Alessandro M. Vannucchi

Blood (2015) 126 (23): 4087.

https://doi.org/10.1182/blood.V126.23.4087.4087

Published: 2015

Journal Articles

Mutational Landscape of Patients with Myelofibrosis That Do Not Harbor Mutations in JAK2, MPL and Calreticulin Driver Genes

Giada Rotunno, MSc, Paola Guglielmelli, MD PhD, Annalisa Pacilli, PhD, Tiziana Fanelli, MSc, Carmela Mannarelli, MSc, Alessandro Pancrazzi, BS, Alessandro M. Vannucchi

Blood (2015) 126 (23): 4091.

https://doi.org/10.1182/blood.V126.23.4091.4091

Published: 2015

Journal Articles

A Greater Mutational Complexity May Contribute to the Differential Prognostic Impact of Type 1/Type 1-like Versus Type 2/Type2-like Calreticulin Mutations in Primary Myelofibrosis

Paola Guglielmelli, MD PhD, Giada Rotunno, MSc, Tiziana Fanelli, MSc, Annalisa Pacilli, PhD, Laura Calabresi, BiSci, Alessandro Pancrazzi, BS, Alessandro M. Vannucchi

Blood (2015) 126 (23): 1627.

https://doi.org/10.1182/blood.V126.23.1627.1627

Published: 2015

Journal Articles

JAK2V617F Clonal Architecture in MPNs during JAK2 Inhibitor Treatment

Annalisa Pacilli, PhD, Paola Guglielmelli, MD PhD, Tiziana Fanelli, MSc, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Rajmonda Fjerza, MD, Alessandro M. Vannucchi

Blood (2015) 126 (23): 1630.

https://doi.org/10.1182/blood.V126.23.1630.1630

Published: 2015

Journal Articles

Driver Mutations and Prognosis in 1118 Patients with Primary Myelofibrosis

Ayalew Tefferi, MD, Paola Guglielmelli, PhDMD, Terra L. Lasho, PhD, Yoseph Elala, MD, Tiziana Fanelli, MSc, Naseema Gangat, MBBS, Christy Finke, BS, Giada Rotunno, MSc, Curtis A. Hanson, MD, Rhett P. Ketterling, MD, Animesh Pardanani, MBBS, PhD, Alessandro M. Vannucchi, MD

Blood (2015) 126 (23): 2801.

https://doi.org/10.1182/blood.V126.23.2801.2801

Published: 2015

Journal Articles

Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm

Blood (2015) 126 (23): 2803.

https://doi.org/10.1182/blood.V126.23.2803.2803

Published: 2015

Journal Articles

Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients

Paola Guglielmelli, MD PhD, Giada Rotunno, Annalisa Pacilli, PhD, Elisa Rumi, MD, Vittorio Rosti, MD, Federica Delaini, MD, Margherita Maffioli, MD, Tiziana Fanelli, MSc, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Raimonda Fjerza, MD, Daniela Pietra, PhD, Daniela Cilloni, MD, Francesco Passamonti, Alessandro Rambaldi, MD, Giovanni Barosi, MD, Tiziano Barbui, MD, Mario Cazzola, MD, Alessandro M. Vannucchi, MD

Blood (2015) 126 (23): 351.

https://doi.org/10.1182/blood.V126.23.351.351

Published: 2015

Journal Articles

JAK2 V617F Complete Molecular Remission in Long-Term Follow-up of Patients with Polycythemia Vera and Essential Thrombocythemia Treated with Ruxolitinib

Lisa Pieri, MDPhD, Alessandro Pancrazzi, MSc, Annalisa Pacilli, PhD, Claudia Rabuzzi, BSci, Giada Rotunno, MSc, Paola Guglielmelli, MD PhD, Rajmonda Fjerza, MD, Chiara Paoli, MSc, Tiziana Fanelli, MSc, Alberto Bosi, MD, Srdan Verstovsek, MD PhD, Alessandro Maria Vannucchi, MD

Blood (2014) 124 (21): 3185.

https://doi.org/10.1182/blood.V124.21.3185.3185

Published: 2014

Journal Articles

A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group

Blood (2014) 124 (21): 3192.

https://doi.org/10.1182/blood.V124.21.3192.3192

Published: 2014

NARROW

MAF Induces Inflammatory Mediators Involved in the Pathogenesis of Primary Myelofibrosis

Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group

Prognotic Impact of Mutations in Systemic Mastocytosis

Integrative Analysis of Copy Number and Gene Expression Data Suggests Novel Pathogenetic Mechanisms in Primary Myelofibrosis

Mutational Profile of Patients with Polycythemia Vera Treated with Ruxolitinib in the Phase III Controlled Response Study

Mutational Landscape of Patients with Myelofibrosis That Do Not Harbor Mutations in JAK2, MPL and Calreticulin Driver Genes

A Greater Mutational Complexity May Contribute to the Differential Prognostic Impact of Type 1/Type 1-like Versus Type 2/Type2-like Calreticulin Mutations in Primary Myelofibrosis

JAK2V617F Clonal Architecture in MPNs during JAK2 Inhibitor Treatment

Driver Mutations and Prognosis in 1118 Patients with Primary Myelofibrosis

Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm

Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients

JAK2 V617F Complete Molecular Remission in Long-Term Follow-up of Patients with Polycythemia Vera and Essential Thrombocythemia Treated with Ruxolitinib

A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only